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ttp://dx.doi.org/10.1016/j.ajpath.2012.12.032Vascular endothelial growth factor A (VEGF-A) is a validated therapeutic target in several angiogenic-
and vascular permeabilityerelated pathological conditions, including certain cancers and potentially
blinding diseases, such as age-related macular degeneration and diabetic retinopathy. We and others
have shown that VEGF-A also plays an important role in neuronal development and neuroprotection,
including in the neural retina. Antagonism of VEGF-A function might therefore present a risk to neuronal
survival as a signiﬁcant adverse effect. Herein, we demonstrate that VEGF-A acts directly on retinal
ganglion cells (RGCs) to promote survival. VEGF receptor-2 signaling via the phosphoinositide-3-kinase/
Akt pathway was required for the survival response in isolated RGCs. These results were conﬁrmed in
animal models of staurosporine-induced RGC death and experimental hypertensive glaucoma. Impor-
tantly, we observed that VEGF-A blockade signiﬁcantly exacerbated neuronal cell death in the hyper-
tensive glaucoma model. Our ﬁndings highlight the need to better deﬁne the risks associated with use of
VEGF-A antagonists in the ocular setting. (Am J Pathol 2013, 182: 1379e1390; http://dx.doi.org/
10.1016/j.ajpath.2012.12.032)Supported by the Medical Research Council (G0901303), in part by the
Medical Research Council Dorothy Hodgkin Postgraduate Award, the
Helen Hamlyn Trust, Fight for Sight, the National Institute for Health
Research Biomedical Research Centre Moorﬁelds, and the University
College London Institute of Ophthalmology.Vascular endothelial growth factor A (VEGF-A) was initially
identiﬁed as a vascular permeability factor and endothelial
cell mitogen. Since then, it has been shown to have numerous
roles outside the vasculature, perhaps most signiﬁcantly in the
nervous system. Neurons express VEGF receptor (VEGFR)-1
and VEGFR-2, and are able to respond to VEGF-A.1
Furthermore, neuropilins, which are important receptors for
neuronal development and function, are also coreceptors for
the heparin-binding VEGF164 and VEGF188 isoforms.2
Studies have revealed neurodevelopmental, neurotrophic,
and neuroprotective roles for VEGF-A in a variety of nervous
tissues. In vitro, VEGF-A can protect neurons against
hypoxia, glutamate excitotoxicity, and deprivation of serum,
oxygen, or glucose,3e5 and mediate neuronal migration,
axonal outgrowth, and Schwann cell proliferation.6,7 In vivo,
VEGF-A can rescue retinal neurons after optic nerve axot-
omy,8 protect neural tissues through hypoxic preconditioning
in ischemia-reperfusion injury,9 improve function in rodent
models of amyotrophic lateral sclerosis10 and cerebral
ischemia,11 and mediate neuroprotection during developmentstigative Pathology.
.via the coreceptor neuropilins.12 VEGF-A appears to exert
these effects directly on neuronal cells, independently of its
vascular actions, and may even be important for maintenance
of neuronal circuitry.13
Given that antagonism of VEGF-A function is used as
a therapeutic strategy for numerous pathological conditions,
including various types of cancer, choroidal neovascularization
associated with age-related macular degeneration, and macular
edema associated with diabetes mellitus and retinal vein
occlusion, a better understanding of the roles of VEGF-A in the
nervous system is critical.14,15 This therapeutic strategy is also
being explored for additional conditions in which vascular
growth and permeability are important, such as neovascular
glaucoma and ﬁbrotic complications of glaucoma ﬁltration
surgery.16 Given the functional and protective roles of VEGF-A
Foxton et alin the nervous system, these treatments might have unexpected
adverse effects on neural function, particularly in the eye.
With this in mind, we sought to explore the mechanism by
which VEGF-A exerts its neuroprotective effects. We ﬁrst
determined if VEGF-A can act directly on isolated retinal
ganglion cells (RGCs). Having established that VEGF-A
directly prevents RGC apoptosis via VEGFR-2 and phos-
phoinositide-3-kinase (PI3K)/Akt signaling, we used two
different animal models to study RGC death in vivo. Our
ﬁndings suggest a neuroprotective role for VEGF-A in
models of acute toxicity and hypertensive glaucoma, and
highlight the need for rigorous assessment of the long-term
impact of VEGF-A inhibition on retinal neurons.
Materials and Methods
Animals
All animalswereobtained fromHarlanLaboratories (Shardlow,
United Kingdom) and used according to Home Ofﬁce (http://
www.homeofﬁce.gov.uk/science-research/animal-research,
last accessed February 17, 2013) and the Association for
Research in Vision and Ophthalmology Statement for the Use
of Animals in Ophthalmic and Vision Research guidelines
(http://www.arvo.org/About_ARVO/Policies/Statement_for_
the_Use_of_Animals_in_Ophthalmic_and_Visual_Research,
last accessed February 17, 2013).
RGC Isolation and Culture
Weused an immunomagnetic cell separation protocol based on
Sappington et al,17 with modiﬁcations. Retinas from postnatal
day 1 Sprague-Dawley rats were dissociated as previously
described.To ensure purity ofRGCs,we removedmacrophages
ﬁrst. The pellet was resuspended in Dulbecco’s modiﬁed
essential media (Invitrogen, Paisley, UK) with rabbit antierat-
macrophage antiserum (1:100; Accurate Chemical, Westbury,
NJ). The solution was then incubated with goat anti-rabbit
secondary antibody conjugated to magnetic microbeads and
separated using an automagnetic activated cell sorter (Miltenyi
Biotec, Cologne, Germany). The negative fraction was incu-
bated with mouse anti-rat Thy1.1 antibody (1:125; BD Phar-
mingen, SanDiego, CA), followed by secondary rat anti-mouse
IgG1 antibody conjugated to magnetic beads (Miltenyi Biotec).
Automagnetic activated cell sorter separation was performed,
leaving Thy1.1-positive RGCs, which are reported to comprise
93% of Thy1.1-positive cells in the retina.18
Before seeding, culture vessels were coated with 0.01
mg/mL poly-D-lysine (Sigma-Aldrich, Dorset, UK) and 0.01
mg/mL laminin (Roche Applied Science, West Sussex, UK).
Cells were seeded in 4-well plates (Nunc, Roskilde, Denmark)
on 13-mm glass coverslips at 2.5 104 cells per well, and 5
105 cells per well on 12-well plates for real-time PCR. Cells
were grown in serum-free Neurobasal-A medium, as previ-
ously described,17 and maintained at 37C in 5% CO2.
Because RGCs require growth factors to survive, it was
necessary to dissect protective properties of VEGF-A from1380those offered by growth factors already present. Cells
received full medium at day in vitro (DIV) 0 and DIV 1; then,
no further medium was used until treatment on DIV 5. This
ensured sufﬁcient cells survived for assays without masking
the beneﬁcial effects of VEGF-A by other neuroprotectants.
Mouse VEGF164, VEGF120 (R&D Systems, Abingdon,
UK), VEGF-E (Isolate D1701 with His tag, CRV007;
Cell Sciences, Canton, MA), placental growth factor
(PlGF)-1, and PlGF-2 (Peprotech, London, UK), at 2.5 nmol/
L ﬁnal concentration, were added in Neurobasal-A (Invi-
trogen) on DIV 5, 24 hours before toxicity treatment. These
cells were added in media minus supplements or growth
factors to media covering the monolayer, because removal of
all survival factors was too damaging. For H2O2 treatment,
cell culture medium was removed, and 500 mL of 10 mmol/L
H2O2, with or without VEGFR ligands in Neurobasal-A, was
added for 5 hours. Because of staurosporine (SSP) potency, it
was necessary to add this onto media already present. SSP,
with or without VEGFR ligands (1 mmol/L), was added for
24 hours in Neurobasal-A. The PI3K inhibitors, LY-294,002
(0.1 to 10 mmol/L) and wortmannin (0.3 to 30 nmol/L), were
added 10 minutes before VEGFR agonist pretreatment in
Neurobasal-A. Pan-caspase inhibitors Z-VAD-Fmk and Q-
VD-Oph, used individually or in combination, were added
simultaneously with H2O2 or SSP at 100 mmol/L. Equivalent
concentrations of dimethyl sulfoxide (DMSO) were included
as controls for SSP, PI3K, and caspase inhibitor experiments.
Cell Survival Assay
Cell survival was determined using calcein AM dye (Invi-
trogen) to quantify viable cells remaining after treatments,
based on previously published methods.19 Calcein AM is
a cell-permeable, ﬂuorogenic esterase substrate, which is
hydrolyzed by intracellular esterases in living cells and
converted into the ﬂuorescent product, calcein. We imaged
three random nonoverlapping ﬁelds of each well, on
duplicate coverslips at 10 magniﬁcation using a BX51
epiﬂuorescence microscope with a Retiga SRV camera
(QImaging, Surrey, BC, Canada). At least 200 cells were
counted per N, using an automated cell counting program
(Image Pro Plus 6.2; Media Cybernetics, San Diego, CA).
The survival rate was expressed as a percentage of the total
number of cells in control wells at each time point.
Real-Time PCR
For in vitro real-time PCR, cells received full media, plus or
minus 2.5 nmol/L VEGF164 or PlGF-1, at DIV 1, 2, and 5.
At DIV 7, total RNA was isolated using the RNEasy kit
(Qiagen, Sussex, UK). For in vivo studies, eyes were stored
in RNAlater (Invitrogen) until RNA was extracted. Real-
time PCR was conducted using the Taq-Man Gene
Expression Assay (Applied Biosystems, Warrington, UK).
To detect expression of the target gene, the following
assays were used: VEGF (Rn00582935_m1), VEGFR-2ajp.amjpathol.org - The American Journal of Pathology
VEGF-A Prevents Retinal Neuron Death(Rn00564986_m1), VEGFR-1 (RN00570815_m1), and b-
actin (RN00667869_m1). Expression levels of target genes
were determined by the relative quantiﬁcation method
using b-actin as an endogenous control.
TUNEL Staining
The TUNEL assay quantiﬁed apoptotic cells in vitro and
in whole mount retinas, according to manufacturer’s
instructions (Promega, Southampton, UK). For RGCs
in vitro, cells were ﬁxed in 4% paraformaldehyde (PFA)
for 15 minutes, permeabilized with 0.2% Triton X-100 in
PBS (T-PBS), before the TUNEL reaction. Coverslips
were mounted onto glass slides, and images were obtained
of six nonoverlapping ﬁelds taken from duplicate cover-
slips at 10 magniﬁcation using an Olympus BX51
microscope (Olympus, Essex, UK) with a Retiga SRV
camera (QImaging). DAPI- and TUNEL-positive cells
were counted (minimum, 500 cells per coverslip). The
number of TUNEL-positive cells was subtracted from
DAPI-positive cells to give TUNEL-negative (non-
apoptosing) cells and averaged per ﬁeld. Each N repre-
sents independent cell separations.
For whole mounts, animals were CO2 asphyxiated, then
eyes were ﬁxed in 4% PFA. Retinas were permeabilized in
3% T-PBS for 2 hours. The TUNEL protocol was performed,
and retinas were washed in 0.3% T-PBS with 5 mmol/L DAPI
and then ﬂat mounted in Vectashield (Vector Laboratories,
Peterborough, UK). To quantify TUNEL-positive neurons,
we used a Zeiss 700 confocal microscope (Zeiss, Oberko-
chen, Germany), taking 10-mmZ-stacks through the ganglion
cell layer (GCL) at 20 magniﬁcation. Morphological
criteria discriminated nonneuronal (endothelial and glial)
cells from neuronal cells. We took three images on each of
the four petals: close to the optic nerve, the middle, and
periphery of the retina, giving 12 images per whole mount
and sampling approximately 7000 cells. Areas were selected
using only DAPI, and investigators (R.F. and A.F.) were
blinded to treatment groups.
Acute Toxicity Model
Male 10-week-old C57/Bl6 mice were anesthetized with
100 mg/kg ketamine and 0.5 mg/kg xylazine, and pupils
were dilated with 2.5% phenylephrine hydrochloride and
1.0% tropicamide (Bausch and Lomb, Surrey, UK). For
pretreatment, bilateral intravitreal injections of 4 pmol
VEGF120 or PBS vehicle were administered in a 1-mL
volume before injecting SSP or vehicle. Mice recovered for
24 hours after initial injection; then, 1 nmol SSP or 10%
DMSO vehicle, with or without wortmannin in 1 mL, was
administered intravitreally. Animals were sacriﬁced 24
hours later by CO2 asphyxiation. Eyes were enucleated and
ﬁxed in 4% PFA for 4 hours for staining. Investigators (R.F.
and A.F.) were masked to treatment groups until analysis
was complete.The American Journal of Pathology - ajp.amjpathol.orgOcular Hypertension Model
Experimental glaucoma was induced by elevating the intra-
ocular pressure (IOP) via injection of paramagnetic micro-
spheres into the anterior chamber, based on Samsel et al.20
Brieﬂy, 250 to 300 g female exbreeder Brown Norway
rats were housed for 1 week in a constant low-light envi-
ronment (40 to 60 lux) to minimize diurnal ﬂuctuations in
IOP. Rats were anesthetized with 37.5 mg/kg ketamine and
0.25 mg/kg medetomidine hydrochloride, and a toroidal
magnet (Supermagnete, Gottmadingen, Germany) was
placed around the eye, before 25 mL of a solution containing
30 mg/mL 8-mm magnetic microspheres (Bangs Laborato-
ries, Fisher, IN) in HBSS was injected into the anterior
chamber. The magnet drew the beads into the iridocorneal
angle, to impede aqueous drainage from the trabecular
meshwork. Right eyes acted as unoperated on controls. IOP
measurements were taken in awake animals before bead
injection, then every 2 to 3 days using a TonoLab rebound
tonometer (Tiolat, Oy, Finland). The IOP was taken as the
mean of ﬁve readings. To investigate VEGF-A neuro-
protection, 20 pmol of VEGF120, VEGFR-2 Fc chimera
(R&D Systems), IgG, or vehicle controls was injected
intravitreally on days 3 and 10 after induction. Animals were
sacriﬁced on day 17 after induction, and eyes were enucle-
ated and ﬁxed in 4% PFA overnight for TUNEL. All
experiments were performed masked.
Immunostaining
For RGC cultures, cells were ﬁxed in 4% PFA and blocked
with 5% normal goat serum in 0.1% T-PBS for 2 hours.
Primary antibodies were rabbit anti-Thy1 (1:200; Santa Cruz
Biotechnology, Santa Cruz, CA), rabbit antiebIII-tubulin
(1:500; Abcam, Cambridge, UK), rabbit antieVEGFR-2
(1:200; Abcam), goat anti-VEGFR1 (1:100; Santa Cruz
Biotechnology), rabbit antiephospho-Akt (1:200; Cell
Signaling, Beverly, MA), and rabbit antieactive caspase-3
(1:250; R&D Systems). Speciﬁcity for VEGFR-2 was
conﬁrmed using blocking peptide (Abcam). Secondary
antibodies were goat anti-rabbit or donkey anti-goat conju-
gated to Alexa Fluor 488 or 594 (Invitrogen) used at a 1:500
dilution for VEGFR staining and a 1:200 dilution for all other
experiments. Coverslips were mounted onto glass slides in
ProLong Gold with DAPI (Invitrogen).
For retinal whole mounts, animals were sacriﬁced and
retinas were prepared as for TUNEL staining. The tissue
was blocked for 2 hours in 5% donkey serum and 0.3%
T-PBS before primary antibodies were applied overnight.
Secondary antibodies were added for 2 hours in 0.3%
T-PBS. After secondary incubation, the tissue was rinsed in
0.3% T-PBS plus 5 mmol/L DAPI and then ﬂat mounted in
Vectashield (Vector Laboratories, Peterborough, UK).
Primary antibodies used were rabbit antiephospho-Akt
(1:500; Cell Signaling) and goat anti-Brn3a (1:200; Santa
Cruz Biotechnology); secondary antibodies were donkey1381
Foxton et alanti-rabbit conjugated to Alexa Fluor 633 and donkey anti-
goat conjugated to Alexa Fluor 594 (1:1000; Invitrogen).
Fluorescein-conjugated Griffonia simplicifolia isolectin B4
(1:400; Vector Laboratories, Peterborough, UK) stained
blood vessels. Controls were no primary antibody and
relevant IgG isotypes. Images of cells and retinas were taken
on a Zeiss 700 confocal microscope.
Optic Nerve Sections
Optic nerves were ﬁxed overnight in Karnovsky’s solution at
4C. Specimens were osmicated for 2 hours in 1% (w/v)
osmium tetroxide and then dehydrated in 100% ethanol.
Optic nerves were then incubated in propylene oxide for 30
minutes and placed in a 50:50 mixture of propylene
oxide:araldite overnight. This solution was changed to 100%
araldite and incubated overnight at 60C. Semithin sections
(0.75 mm thick) were cut and stained with 1% toluidine blue/
borax (TB) in 50% ethanol before examination by light
microscopy. For quantiﬁcation, three nonoverlapping images
were taken at 63 magniﬁcation, in the center, midway, and
periphery of the optic nerve, using an Olympus BX51
microscope with a Retiga 2000R camera (QImaging).
Nonviable/dying axons with TB accumulated were counted
in two sections per optic nerve, averaged per section, and
then expressed as dying axons per mm2. At least three optic
nerves were quantiﬁed per treatment group.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism
software version 4 (GraphPad Software, La Jolla, CA). In all
instances, one-way analysis of variance with a Newman-
Keul’s post hoc test was used, except for RGC cultures, when
analysis of variance with repeated measures was used. To
analyze real-time PCR results, CT values were normalized to
b-actin and statistics were performed on DCT values. Results
are means  SEM unless stated, with each N representing an
individual cell culture separation or retina; N was at least three
for each statistical analysis. P < 0.05 was considered
signiﬁcant.
Results
Characterization of Primary RGC Cultures
We have previously demonstrated that VEGF-A can protect
retinal neurons from death induced by ischemia-reperfusion
injury.9 Because this in vivo model involves potential indirect
effects of blood ﬂow and paracrine-mediated protection from
endothelial or other retinal cell types, we used primary RGC
cultures to probe the mechanisms of VEGF-Aemediated
neuroprotection. RGCs were used because relatively homo-
geneous cultures can be obtained compared with other retinal
neurons, and they are relevant to many retinal pathological
conditions.21 We conﬁrmed the purity of our primary RGC1382cultures by immunostaining for the RGC marker, Thy-1, and
neuron-speciﬁc bIII-tubulin. At DIV 5, RGC cultures were
>95% positive for both markers (Supplemental Figure S1).
The cells formed dense networks of neurites and were capable
of surviving for weeks in culture.
Expression and Function of VEGFRs in Cultured RGCs
In vivo, RGCs express both VEGF-A and its receptors.1 By
using real-time quantitative PCR (qPCR), we demonstrated
that VEGFR expression was maintained in our cultured
RGCs. VEGFR-2 was the most abundant receptor, with
relative levels 17-fold higher than those of VEGFR-1 (P <
0.001) (Supplemental Figure S2A). When compared with
primary rat brain microvascular endothelial cells in culture
(donated by Dr. Patric Turowski, UCL Institute of
Ophthalmology, London, UK)), a cell type known to
express functional VEGFRs, the relative levels of VEGFR-2
were ﬁvefold higher and of VEGFR-1 were fourfold
lower in RGCs and ratios of VEGFR-2/VEGFR-1 were
approximately 17:1 in RGCs and 1:1 in endothelial cells
(Supplemental Figure S2, A and B).
To determine whether the receptors for VEGF-A are
functional in cultured RGCs, we treated cells with VEGF-A
isoforms VEGF120 and VEGF164; VEGFR-1especiﬁc
PlGF-1 and PlGF-2; and VEGF-E, which is speciﬁc for
VEGFR-2. VEGF164 induced a twofold increase in
VEGFR-2 expression (P < 0.001) (Figure 1A). This was
accompanied by increased VEGFR-2 immunostaining,
particularly along the neurites and perinuclear region:
VEGFR-2 staining in RGCs was predominantly perinuclear
(Figure 1B). Increased immunostaining was also observed
with VEGF120 and VEGF-E treatments (Figure 1B).
VEGFR-1 expression increased approximately 1.6-fold
(P < 0.01) after VEGF164 treatment (Figure 1A). PlGF-1
did not signiﬁcantly modify mRNA expression of either
VEGFR (Figure 1A), nor was the qualitative immuno-
staining pattern altered for PlGF-1 or PlGF-2 (Figure 1B).
Together, these data demonstrate that cultured RGCs
express VEGFR-2 and that receptors are functional.
RGC Responses to Cell Death Agents
To assess the neuroprotective properties of VEGF-A, it was
necessary to identify agents that effectively induce RGC
death in culture. We evaluated nine conditions described in
the literature3,4,22e28 for inducing RGC death (Supplemental
Table S1). RGCs in culture were surprisingly resilient;
agents that induce receptor-mediated apoptosis, including
tumor necrosis factor a, Fas ligand, and IL-1b, failed to
cause RGC death after 1 to 5 days of treatment. Excitotoxic
ligands, N-methyl-D-aspartate, 2-amino-3-(5-methyl-3-oxo-
1,2-oxazol-4-yl) propanoic acid, and glutamate, also failed
to cause signiﬁcant cell death, even with 5 days of 500
mmol/L ligand. However, RGCs in culture have previously
been invulnerable to N-methyl-D-aspartateemediated cellajp.amjpathol.org - The American Journal of Pathology
Figure 1 Primary RGC cultures express VEGF-A
and its receptors. A: Real-time qPCR analysis of
VEGFR-2, VEGFR-1, and VEGF-A. Relative expression
levels of VEGFR-1 and VEGFR-2 were signiﬁcantly
elevated after VEGF164 treatment compared with
control, whereas PlGF had no effect. In contrast,
VEGF-A RNA levels were slightly attenuated with
VEGF164 supplementation, and enhanced in
response to PlGF-1. **P < 0.01, ***P < 0.001
(N Z 6). Data are given as means  SD.
B: Immunolabeling of VEGFR-2 (green) and bIII-
tubulin (red) in RGCs cultured in control medium or
with 2.5 nmol/L PlGF-1, PlGF-2, VEGF120, VEGF164,
or VEGF- E for 5 days. Original magniﬁcation, 63.
VEGFR-2 immunoreactivity increased after VEGF120,
VEGF164, or VEGF-E supplementation, with punctate
staining observed both perinuclearly and on
neurites. In contrast, VEGFR-2 expression did not
increase and remained perinuclear in control and
PlGF-1e and PlGF-2etreated RGCs. Scale bar Z
10 mm.
VEGF-A Prevents Retinal Neuron Deathdeath.29 Even hypoxia for up to 24 hours did not induce
signiﬁcant cell death (1% O2) (Supplemental Table S1).
Conditions that caused signiﬁcant RGC death were
growth factor withdrawal and exposure to paraquat, SSP, or
H2O2 (Supplemental Table S1). From these, H2O2, used to
model oxidative stress in vitro, and SSP, a non-speciﬁc
protein kinase inhibitor that broadly activates cellular
death pathways,30 were chosen because they were optimal
for our assays. Both induced consistent, dose-dependent
RGC death (P < 0.05).
VEGF-A Protects RGCs via VEGFR-2, Independent of
Neuropilins
To examine VEGF-mediated effects on RGC survival,
cultures were pre-treated with VEGF family ligands with
different binding properties for VEGFR-1, VEGFR-2, and
neuropilins. RGCs were pre-treated at DIV 5 for 24 hours
with media supplemented with a ﬁnal concentration to
2.5 nmol/L of the agonists, followed by addition of 10 mmol/L
H2O2 for 5 hours or SSP for 24 hours. Of the different
VEGFR ligands tested, VEGF164 (P < 0.01), VEGF120
(P < 0.05), and VEGF-E (P < 0.01) all increased RGC
survival by approximately 50% (Figure 2A). In contrast,
PlGF-1 and PlGF-2 did not protect against H2O2-mediated
cell death. A similar pattern emerged for SSP treatment. SSP
(1 mmol/L) induced approximately 25% death of RGCs,
which was completely reversed by 24-hour pretreatment withThe American Journal of Pathology - ajp.amjpathol.orgVEGF164, VEGF120, or VEGF-E (all P < 0.001). Again,
both PlGF-1 and PlGF-2 failed to offer detectable protection.
These data indicate that VEGFR-2 is required for
protection of RGCs, consistent with our ﬁndings in vivo.9 It
appeared that the heparin-binding domain of VEGF-A was
not essential, because the VEGF120 isoform and VEGF-E
that lack this domain rescued cells with similar potency to
heparin-binding VEGF164. These data further suggest that
neuropilin receptors are not required for protection, because
VEGF120 and VEGF-E, which exhibit little or no binding
to neuropilin-1 and neuropilin-2,2,31,32 were protective,
whereas PlGF-2, which binds to both neuropilins, did not
enhance survival. We decided to use VEGF120 in subse-
quent experiments because this isoform produced consistent
protection (Figure 2A) and induced fewer adverse effects on
intravitreal injection in vivo.9
VEGF-A Is Able to Protect against Apoptotic,
Caspase-Dependent Cell Death
We sought to characterize the mechanism of VEGF-Ae
mediated neuroprotection in further detail. TUNEL staining
was used to deﬁne whether cell death was associated with
DNA fragmentation, commonly associated with apoptosis.
Inhibitors and immunostaining were also used to determine
whether modulation of caspase signaling was associated
with VEGF-Aemediated neuroprotection. TUNEL staining
revealed that H2O2 treatment signiﬁcantly reduced viable1383
Figure 2 VEGF-A protects against apoptotic, caspase-
dependent death via VEGFR-2, independent of neuro-
pilins. A: The RGCs at DIV 5 were pre-treated for 24 hours
in media, with or without VEGF120, VEGF164, VEGF-E,
PlGF-1, or PlGF-2 (2.5 nmol/L). H2O2 (10 mmol/L; left
panel) was added to the cells for 5 hours, and SSP (1
mmol/L; right panel) was added for 24 hours. VEGF164,
VEGF120, and VEGF-E all increased survival of the
cultures, whereas neither PlGF-1 nor PlGF-2 prevented
RGC death. *P < 0.05, **P < 0.01, and ***P < 0.001
(NZ 5 to 6). B: Cells were treated with H2O2 (left panel)
or SSP (right panel) and TUNEL stained. The percentage
of TUNEL-negative, viable RGCs increased after pretreat-
ment with 2.5 and 5.0 nmol/L VEGF120. *P < 0.05,
**P < 0.01 (NZ 8). Data are given as means  SEM. C:
RGCs were incubated with pan-caspase inhibitors, Z-VAD-
Fmk and Q-VD-Oph, before H2O2 or SSP exposure. Caspase
inhibitors largely abolished the toxic response, both
independently and in combination. *P < 0.05, **P <
0.01 (N Z 4 to 8). D: Immunocytochemistry for active
caspase-3 (green) showed increased staining in cells
treated with H2O2 (note condensed caspase-3 staining
around apoptotic nuclei; middle panel) compared with
control cells (left panel). Staining was reduced after
VEGF120 pretreatment (right panel). Cells were coun-
terstained with bIII-tubulin (red) and DAPI (blue).
Original magniﬁcation, 20. Scale bar Z 10 mm.
Foxton et al(TUNEL-negative) cell number by 42% relative to control
(P < 0.001) and that VEGF120 dose dependently aug-
mented survival compared with control, by 31% at 2.5 nmol/L
(P < 0.05) and 50% at 5.0 nmol/L (P < 0.05) (Figure 2B).
These effects were also observed with SSP treatment, for
which VEGF120 exposure signiﬁcantly reduced cell death
(P < 0.05 compared with SSP alone).
Caspase activation is an early step in the initiation of
apoptosis. To determine the role of caspases in H2O2- and
SSP-mediated RGC death, two different caspase inhibitors,
Z-VAD-Fmk and Q-VD-Oph, were used. These inhibitors
have differential afﬁnities for individual caspases; therefore,
they must be used in combination to fully differentiate be-
tween caspase-dependent and caspase-independent death.33
Both Z-VAD-Fmk and Q-VD-Oph signiﬁcantly increased1384the percentage of viable RGCs from 39% to 72% and 68%,
respectively (both P < 0.01), and to 63% (P < 0.05) when
combined (Figure 2C). Findings were similar for SSP-
induced cell death (Figure 2C).
Because caspase activity and DNA fragmentation are
involved in H2O2- and SSP-induced RGC death, we sought
to determine whether the neuroprotective effects of VEGF-A
involve modulation of caspase activation. Immunostaining
conﬁrmed an increase in activated caspase-3 levels in the
presence of H2O2, and pretreatment of cells with VEGF120
markedly reduced the amount of activated caspase-3
(Figure 2D). Taken together, these data suggest that H2O2
and SSP initiate apoptotic, caspase-dependent death in
RGCs, and that VEGF-A signaling via VEGFR-2 inhibits
caspase-3 activation to promote RGC survival.ajp.amjpathol.org - The American Journal of Pathology
Figure 3 Neuroprotection by VEGF120 is PI3K/
Akt mediated. A and B: Increasing concentrations
of PI3K inhibitors, LY294,002 (left panel) and
wortmannin (right panel), were added to RGCs
immediately before VEGF120 pretreatment, before
H2O2 (A) or SSP (B) was added to kill the cells.
Both LY294,002 and wortmannin dose depen-
dently abolished the protective effect of VEGF120.
*P < 0.05 (NZ 5 to 6). Data are given as means 
SEM. C: Immunocytochemistry revealed cyto-
plasmic expression of phospho-Akt (green) in
control cultures, which was reduced after H2O2
exposure. In cells rescued with VEGF120, phospho-
Akt (pAkt) reactivity was similar to control and
was reduced with LY294,002 treatment. Cells were
counterstained with bIII-tubulin (red) and DAPI
(blue). Original magniﬁcation, 63. Scale bar Z
10 mm.
VEGF-A Prevents Retinal Neuron DeathPI3K/Akt Signaling Pathways Mediate VEGF-A
Neuroprotection in Vitro
The PI3K/Akt signaling pathway is involved in numerous
cellular functions, and has been identiﬁed as central for
survival of many cell types, including neurons.5 To deter-
mine whether VEGF-A mediates neuroprotection via PI3K/
Akt in RGCs, we ﬁrst explored the activation status of Akt
in cultured cells. In the presence of H2O2, RGC phospho-
Akt levels were reduced, an effect prevented by VEGF120
pretreatment (Figure 3C). Furthermore, pretreatment of
RGCs with the PI3K inhibitor, LY294,002, blocked
VEGF120-induced Akt phosphorylation. These data indicate
that Akt signaling is activated during VEGF120-mediated
protection of RGCs.
To conﬁrm that VEGF-A acts via the PI3K/Akt signaling
axis, cells were exposed to PI3K inhibitors during
VEGF120 pretreatment and the effects on neuroprotection
were monitored. LY294,002 or wortmannin alone did not
induce RGC death (Supplemental Figure S3, A and B).
When added to RGCs immediately preceding VEGF120,
LY294,002 dose dependently abolished the survival-
enhancing properties of VEGF120 against H2O2 (P <
0.05) (Figure 3A). Similar results were obtained with
wortmannin (P < 0.05). When the corresponding experi-
ments were conducted using SSP, attenuation of VEGF120
protection was observed at the highest inhibitor doses tested
(P < 0.05) (Figure 3B).The American Journal of Pathology - ajp.amjpathol.orgVEGF-A Protects RGCs in an in Vivo Acute Toxicity
Model via PI3K-Dependent Pathways
Using primary RGC cell cultures, we have illustrated the
direct neuroprotective function of VEGF-A, and implicated
signaling pathways involved. To examine the applicability
of these ﬁndings in vivo, acute toxin-induced retinal cell
death was initiated by intravitreal injection of SSP. Mice
were pre-treated with an intravitreal injection of 4 pmol
VEGF-A or vehicle for 24 hours before receiving 1 nmol
SSP or vehicle for a further 24 hours. Injection of SSP
signiﬁcantly increased the number of TUNEL-positive cells
in the GCL (68.9  16.8 cells per retina), compared with
saline-injected (12.3  3.3 cells per retina; P < 0.01) or
DMSO vehicle controls (6.0  1.2 cells per retina; P <
0.001) (Figure 4, A and C). VEGF120 pretreatment signif-
icantly protected against SSP-induced toxicity, reducing
apoptotic nuclei by 57% compared with vehicle control
(29.8  6.4 cells per retina; P < 0.01). To explore if VEGF-
Aemediated neuroprotection is mediated by PI3K signaling
in vivo, the PI3K inhibitor wortmannin, was injected si-
multaneously with SSP, after VEGF120 pretreatment.
Wortmannin alone did not increase RGC apoptosis com-
pared with controls (Supplemental Figure S3C), but it fully
reversed the protective effects of VEGF120 against SSP
toxicity (21.79  4.2 versus 53.29  9.1 cells per retina;
P < 0.05) (Figure 4B), suggesting a fundamental role for
PI3K in VEGF-Aemediated neuroprotection.1385
Figure 4 VEGF120 protects against SSP-
induced retinal cell death in vivo via the PI3K/
Akt pathway. A: VEGF120 protects against SSP-
induced cell death in the mouse retina. DMSO
vehicle did not increase the number of TUNEL-
positive cells higher than PBS vehicle control
(N Z 6 to 8), whereas SSP elevated apoptotic
nuclei counts by approximately 5.5-fold (P <
0.01, N Z 12). Pretreatment with VEGF120 pro-
tected against SSP toxicity, reducing TUNEL-
positive cells by 57%. **P < 0.01, ***P <
0.001 (N Z 10). B: Treatment with 1 nmol of the
PI3K inhibitor, wortmannin, reversed VEGF120-
mediated neuroprotection (*P < 0.05, N Z 14).
The PBS/SSP data in this ﬁgure were taken from
the experiment shown in Figure 4A. Data are given
as means  SEM. C: Representative images of
PBS/PBS- (left panel), PBS/SSP- (middle panel),
and VEGF120/SSP- (right panel) injected retinas,
stained for DAPI and TUNEL (white; arrows).
Original magniﬁcation, 20. Scale bar Z 50 mm.
Foxton et alVEGF-A Protects against RGC Death in an Ocular
Hypertension Model
The protective effect of VEGF-A was also explored in an
in vivo model of experimental glaucoma, in which RGC
death was induced by mechanically increasing IOP. In
patients with ocular hypertensive glaucoma, elevated IOP
caused by obstruction of aqueous outﬂow is a key risk factor
in disease pathophysiological characteristics.34 Animal
models have been developed to mimic blockage of the
trabecular meshwork, including use of magnetic micro-
spheres drawn into the iridocorneal angle to reduce
outﬂow.20 This model was used herein to validate the
neuroprotective properties of VEGF-A in rats.
Injection of magnetic beads into the anterior chamber
triggered a signiﬁcant and prolonged increase in IOP. The
mean IOP averaged over the full length of the experiment
for control, nonebead-injected eyes was 19.8  0.6 mmHg,
compared with 43.3  3.3 mmHg for bead-injected eyes
(P < 0.001) (Figure 5A). The peak IOP was 22.8  0.6
mmHg for control eyes versus 55.2  3.5 mmHg for bead-
injected eyes (P < 0.001). Intravitreal injection of VEGF120
did not affect IOP in bead-injected eyes (Figure 5A); the
mean and peak IOP levels were all similar for VEGF120-
and vehicle-injected eyes.
To investigate if expression of endogenous VEGF-A and its
receptors was altered after IOP elevation, retinas were
analyzed by real-time qPCR. No change in mRNA levels for
VEGF-A (Figure 5B), VEGFR-2, or VEGFR-1 (Supplemental
Figure S4) was detected between control and retinas from
hypertensive eyes.
Cell death in GCL was assessed using TUNEL staining,
which has been shown to increase in patients with1386glaucoma35,36 and correlates with RGC loss and optic nerve
degeneration in animal glaucoma models.37e39 In eyes in
which magnetic beads were injected but pressure did not
increase (because of incomplete blockage of the iridocorneal
angle), the numbers of TUNEL-positive cells were not
signiﬁcantly different from those of nonebead-injected
control (Figure 5C). These eyes were excluded from our
studies. In eyes in which the IOP increased after microsphere
injection, there was a signiﬁcant elevation in TUNEL-positive
apoptotic nuclei in the GCL, which is mostly composed of
RGCs, as previously reported.20,40 The number of apoptotic
nuclei increased by approximately 16-fold, from 1.9  0.5 to
31.0 10.0 cells per retina (P< 0.01) (Figure 5C), conﬁrming
that a high IOP leads to apoptosis of RGCs. Treatment with an
intravitreal injection of 20 pmol VEGF120 on days 3 and 10
after glaucoma induction reduced apoptotic cell counts by
77% (P< 0.01), from 31.0 10.0 to 7.0 1.6 cells per retina
(Figure 5, D and F), indicating that VEGF120 protects retinal
neurons against apoptotic cell death in experimental glaucoma.
Furthermore, we observed extensive damage to the optic nerve
in histologically stained transverse sections from hypertensive
eyes. There were approximately 20-fold more degenerating
axons in animals with a high IOP, from 0.6 0.3 to 12.4 2.8
axons per mm2 optic nerve (P < 0.01). This damage was
reduced by 63% (P< 0.05) to 4.6 0.94 axons per mm2 optic
nerve in eyes treated with intravitreal VEGF120 (Figure 5, E
and G).
To determine whether VEGF-A affects PI3K/Akt
signaling during neuroprotection in vivo, we stained whole
mount retinas from the ocular hypertension model for
phospho-Akt. Immunostaining revealed barely detectable
levels of phospho-Akt in control and PBS-treated glau-
comatous retinas (Figure 5H). In response to VEGF120ajp.amjpathol.org - The American Journal of Pathology
Figure 5 VEGF120 protects RGCs against
apoptosis in experimental hypertensive glaucoma,
with a corresponding increase in phospho-Akt. A:
Bead injection triggers a signiﬁcant increase in
IOP, in both PBS- and VEGF120-beadeinjected (B)
compared with control, nonebead-injected (NB)
rat eyes (P < 0.001, N Z 10). B: VEGF mRNA
remained at control levels in bead-injected eyes
(NZ 4). C: A signiﬁcant increase in TUNEL-positive
nuclei in the GCL was observed for bead-injected
eyes with an increase in IOP, but not for bead-
injected eyes in which pressure did not increase
(N Z 5 to 7). D: In PBS bead-injected eyes (B),
apoptotic cell number increased 16-fold (N Z 8)
higher than control (NB), but was markedly
reduced by 77% in eyes treated with 20 pmol
VEGF120 (NZ 8). Data are given as means  SEM.
E: VEGF120 also protected against optic nerve
damage. Extensive damage was found to the optic
nerve in histologically stained transverse sections
from hypertensive eyes, as determined by TB
staining of semithin nerve segment sections.
Approximately 20-fold more degenerating axons
were found in animals with a high IOP, from 0.6 
0.3 to 12.4  2.8 axons per mm2 optic nerve. This
was reduced by 63% to 4.6  0.94 axons per mm2
optic nerve in eyes treated with intravitreal
VEGF120 (E). Data are given as means SEM. *P<
0.05, **P < 0.01 (NZ 3 to 5) (C–E). F: Represen-
tative images of control (left panel), PBS bead-
injected (middle panel), and VEGF120 bead-
injected (right panel) retinas stained for DAPI
(blue) and TUNEL (green), showing that VEGF120
treatment reduces TUNEL staining (arrows) to near-
control levels. G: Representative images of optic
nerve staining, showing, compared to controls, an
increase in TB accumulation from control (left
panel), in PBS bead-injected animals with a high IOP
(middle panel), which was reduced with VEGF120
administration (right panel). Arrows denote
degenerating axons. H: Representative images of
whole-mount staining for phospho-Akt (pAkt; red).
In control (left panel) eyes, pAkt was barely
detectable within the GCL, indicating Akt is not
constitutively phosphorylated in RGCs. This staining
pattern was also observed in PBS bead-injected
(middle panel) groups. However, in VEGF120
treated eyes (right panel), strong pAkt immunore-
activity was observed around Brn-3a (green) positive
RGCs, and vessels stained with isolectin B4 (white).
These images conﬁrm VEGF120 stimulates pAkt
signaling in correlation with its neuroprotective
activity. Original magniﬁcation: 20 (F); 63 (G
and H). Scale bars: 50 mm (F and G); 10 mm (H).
VEGF-A Prevents Retinal Neuron Deathinjection, phospho-Akt immunoreactivity in glaucomatous
retinas increased considerably, particularly in the cell cyto-
plasm, suggesting that the PI3K/Akt pathway is involved in
mediating VEGF120 protection in this model.
VEGF Neutralization Exacerbates Cell Death in the
Ocular Hypertension Model
Finally, to probe the role of endogenous VEGF-A on RGC
survival in our experimental hypertensive glaucoma model,The American Journal of Pathology - ajp.amjpathol.orgsoluble human VEGFR-2/Fc chimera (sVEGFR-2) was
injected intravitreally to neutralize endogenous VEGF-A.
Injection of sVEGFR-2 and human IgG control did not inﬂu-
ence IOP, when compared with control PBS bead-injected
hypertensive eyes (Figure 6A). However, a comparison of cell
death in IgG- and sVEGFR-2etreated hypertensive eyes
revealed that TUNEL-positive apoptotic cells markedly
increased as a result of VEGF neutralization. Apoptosis in the
GCL of the retina was signiﬁcantly elevated by approximately
3.5-fold higher than IgG treatment, from 22.0  7.4 to 79.2 1387
Figure 6 Anti-VEGF treatment exacerbates neuronal injury in experi-
mental hypertensive glaucoma. A: Bead injection triggers a signiﬁcant
increase in IOP over time, in both IgG- and sVEGFR-2 bead-injected (B) eyes
compared with control, nonebead-injected (NB) rat eyes (P < 0.001, NZ
8). B: sVEGFR-2 initiated a large increase in TUNEL-positive cells in the GCL,
higher than contralateral NB (N Z 6 to 9) and IgG vehicle (N Z 6 to 7)
groups. Endogenous VEGF-A is, therefore, neuroprotective under conditions
in which ocular hypertension provokes neuronal damage. **P < 0.01. Data
are given as means  SEM. C: Representative images of control (left
panel), IgG bead-injected (middle panel), and sVEGFR-2 bead-injected
(right panel) retinas stained for DAPI and TUNEL (white; arrows). Original
magniﬁcation, 20. Scale bar Z 50 mm.
Foxton et al26.5 cells per retina (P < 0.01) (Figure 6, B and C), indicating
that neutralization of endogenous VEGF-A further exacerbates
neuronal death in this model.
Discussion
VEGF-A has long been identiﬁed as a critical survival factor
for endothelium,41 but this role has been signiﬁcantly
expanded over recent years to involve other cell types,
including those in both the peripheral and central nervous
systems. In the retina, VEGF-A has been shown to reduce
retinal neuron loss9,42; these ﬁndings have led to discussion
about the long-term neuronal risk of VEGF-A antagonists,43
which are being widely used to treat various ocular condi-
tions.14 In this study, we have used several approaches to
determine the mechanistic basis of neuroprotective effects of
VEGF-A, both in vitro and in vivo. Our ﬁndings highlight
the need to further deﬁne risks that may be associated with
inhibition of VEGF-A in ocular conditions.
In our isolated RGC model, the neuroprotective effects of
VEGF-A were mediated by VEGFR-2. This ﬁnding is
consistent with other published data, including in vitromodels
using hypoxia or serumwithdrawal,4,44 oxidative stress,45 and
glutamate toxicity,22 plus in vivo models, such as optic nerve
transection.8 Several studies have suggested that neuropilin-1
may be involved in VEGF-Aemediated neuroprotection,46
particularly during embryonic development,12 but it has not
yet been established in the adult. Given that VEGF164,
VEGF120, and VEGF-E had comparable neuroprotective1388potency in our study, despite the fact thatVEGF-Edoes not bind
and VEGF120 interacts weakly, if at all, with neuropilin-1, and
that the neuropilin ligand PlGF-2 was not neuroprotective,
neuropilin-1 may not be necessary for VEGF-Aemediated
neuroprotection.
In terms of mechanisms downstream of VEGFR-2,
several pathways have been shown to initiate survival in
neuronal tissues. Outside the ocular setting, mitogen-acti-
vated kinase/mitogen-activated protein kinase/extracellular
signal-regulated kinase,47 protein kinase A,4 and PI3K/Akt,5
alone or acting together, have been shown to mediate neu-
roprotection. In the retina, PI3K/Akt alone9 and dual acti-
vation of PI3K/Akt and ERK-1/28 were shown to enhance
survival. We showed that H2O2- and SSP-triggered RGC
death in vitro was caspase dependent and accompanied by
DNA fragmentation and was, therefore, likely the result of
apoptosis. VEGF-Aemediated cell rescue was prevented by
the PI3K inhibitors, LY-294,002 and wortmannin, which
was validated using wortmannin in the SSP-induced
neuronal cell death model in vivo. These PI3K inhibitors
have been reported to have off-target effects48; however,
future experiments could conﬁrm speciﬁcity using cell-
speciﬁc VEGFR-2 phosphorylation site mutant mice, to
prevent PI3K signal transduction after VEGFR-2 activation,
and also an RGC-selective inducible VEGFR-2 inactivation
model to conﬁrm the role of VEGFR-2 in this pathway.
Nevertheless, phospho-Akt staining in the experimental
glaucoma model corroborated the results from RGC cultures
and further strengthened the case for involvement of PI3K/
Akt signaling.
Importantly, our studies using the ocular hypertension
model of glaucoma demonstrate that VEGF-A signaling is
a critical part of the endogenous response to neural damage.
Administration of a VEGFR-2esoluble receptor signiﬁcantly
increased the number of TUNEL-positive cells in the GCL
during ocular hypertension. We have previously shown that
VEGF-A acts as an endogenous neuroprotective factor as part
of the adaptive response to acute (1-hour) ischemia.9 In our
experimental glaucoma model, there was no change in
VEGF-A or VEGFR levels, yet the data demonstrate that
VEGF-A is required for neuronal survival during a relatively
prolonged insult (>2weeks) to retinal neurons. Taken together,
these data suggest that VEGF-Amay play a constitutive role in
RGC neuroprotection. These data are also consistent with those
of previous studies, in whichVEGF-A depletion via intravitreal
or systemic injection of a neutralizing antibody, or adenoviral
transfection of soluble VEGFR-1, did not affect normal adult
vasculature but did lead to enhanced apoptosis of neurons of
the inner and outer retina.9,42
Do the data from animal models of acute and chronic retinal
disease suggest there is a risk to the human retina exposed to
VEGF-A antagonists?At aminimum, our ﬁndings suggest that
risks to patients with glaucomamay need to be more systemat-
ically and rigorously assessed. Based on full-ﬁeld electro-
retinographic results, it was recently reported that VEGF
neutralization with bevacizumab regressed neovascularizationajp.amjpathol.org - The American Journal of Pathology
VEGF-A Prevents Retinal Neuron Deathand also reduced photoreceptor function in patients with neo-
vascular glaucoma.49 Furthermore, a study observing 49
patients with age-related macular degeneration found that, in
eyes treated with ranibizumab, nerve ﬁber layer thickness was
signiﬁcantly reduced after 1 year of treatment, whereas
untreated control eyes displayed no change.50 However, deter-
mining the risk proﬁle in glaucoma and in the broader retinal
disease population is challenging. First, clinical evidence
suggests that 25% to 35% of RGCs must be lost before there is
a signiﬁcant impact on visual acuity51; therefore, subclinical
retinal neuron death could occur in patients being treated with
VEGF-A antagonists. Second, even if loss of visual acuity is
noted in patients, this could be attributed to the natural course of
diseases, suchasneovascularage-relatedmaculardegeneration,
diabetes mellitus, and glaucoma.21,52,53 Given the enormous
scale of these diseases and potential increasing use of VEGF
antagonists in all of them, even a small effect would be
signiﬁcant.
Lastly, although focused on inherited disease, experi-
mental analyses suggest that the rate of neurodegeneration
in rodents could be as much as two orders of magnitude
greater than in humans, and is related to maximum lifespan
potential.54 Therefore, short-term rodent experiments may
exaggerate the acute risks and long-term monitoring of
patients may be required. Of note is the SEVEN-UP study,
a small-scale (63 patients) follow-up study of patients with
exudative age-related macular degeneration. Despite initial
success in ranibizumab-treated patients in the ﬁrst 24
months, after 7 to 8 years of follow-up and intermittent
treatment, 37% of eyes had acuities of 20/200 or worse, with
many patients exhibiting geographic atrophy.55 These data
are the longest available follow-up of patients treated with
VEGF-A antagonists and need to be expanded before strong
conclusions can be made.
Given the remarkable impact of anti-VEGF strategies on
near-term patient outcomes, one strategy for managing
a potential trade-off between the positive vascular outcomes
and longer-term neuronal risk may be to develop combi-
nation treatments for neovascular conditions that include
neuroprotectants. Further elucidation of the details down-
stream of VEGF-A receptor activation could be critical in
the development of a more holistic strategy for preserving
the proper function of retinal neurons.
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